Candel Therapeutics, Inc. (CADL) Stock Grade

About Candel Therapeutics, Inc.'s fundamentals

Candel Therapeutics is a biotechnology company with a market capitalization of $299.2 million that reported zero revenue growth year-over-year and zero net margin in its latest annual period, reflecting a net loss for the year. The company currently has no dividend yield and lacks meaningful profitability metrics. As a clinical-stage biotech firm, Candel's financial performance is typical of companies in early development stages that are focused on research and development rather than generating commercial revenue.